{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:36:39Z","timestamp":1791592599086,"version":"4.3.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The exposures to hazardous antineoplastic drugs (AD) represent serious risks for health care personnel but the exposure limits are not commonly established because of the no-threshold effects (genotoxic action, carcinogenicity) of many ADs. In this study, we discussed and derived practically applicable technical guidance values (TGV) suitable for management of AD risks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The long-term monitoring of surface contamination by eight ADs was performed in pharmacies and hospitals in the Czech Republic and Slovak Republic in 2008\u20132021; in total 2,223 unique samples were collected repeatedly in 48 facilities. AD contamination was studied by LC-MS\/MS for cyclophosphamide, ifosfamide, methotrexate, irinotecan, paclitaxel, 5-fluorouracil and gemcitabine and by ICP-MS for total Pt as a marker of platinum-based ADs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study highlighted importance of exposure biomarkers like 5-fluorouracil and especially carcinogenic and persistent cyclophosphamide, which should be by default included in monitoring along with other ADs. Highly contaminated spots like interiors of laminar biological safety cabinets represent a specific issue, where monitoring of contamination does not bring much added value, and prevention of staff and separated cleaning procedures should be priority. Rooms and surfaces in health care facilities that should be virtually free of ADs (e.g., offices, kitchenettes, daily rooms) were contaminated with lower frequency and concentrations but any contamination in these areas should be carefully examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and conclusions<\/jats:title><jats:p>For all other working places, i.e., majority of areas in pharmacies and hospitals, where ADs are being prepared, packaged, stored, transported, or administered to patients, the study proposes a generic TGV of 100 pg\/cm<jats:sup>2<\/jats:sup>. The analysis of long-term monitoring data of multiple ADs showed that the exceedance of one TGV can serve as an indicator and trigger for improvement of working practices contributing thus to minimizing of unintended exposures and creating a safe work environment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1235496","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T14:56:21Z","timestamp":1694703381000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Proposals of guidance values for surface contamination by antineoplastic drugs based on long term monitoring in Czech and Slovak hospitals and pharmacies"],"prefix":"10.3389","volume":"11","author":[{"given":"Lucie","family":"Bl\u00e1hov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u011bek","family":"Bl\u00e1ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Dole\u017ealov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Hojdarov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"14791","DOI":"10.1007\/s11356-014-3902-8","article-title":"Antineoplastic compounds in the environment\u2014substances of special concern","volume":"23","author":"K\u00fcmmerer","year":"2016","journal-title":"EnvironSci Pollut Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"and Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1177\/10781552211070933","article-title":"ISOPP standards for the safe handling of cytotoxics","volume":"28","author":"Alexander","year":"2022","journal-title":"J Oncol Pharm Pract."},{"key":"B4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/bjc.2017.161","article-title":"Prioritising action on occupational carcinogens in Europe: a socioeconomic and health impact assessment","volume":"117","author":"Cherrie","year":"2017","journal-title":"Br J Cancer."},{"key":"B5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/00002820-199308000-00005","article-title":"Acute symptoms associated with antineoplastic drug handling among nurses","volume":"16","author":"Valanis","year":"1993","journal-title":"Cancer Nurs."},{"key":"B6","first-page":"432","article-title":"Work practice and some adverse health effects in nurses handling antineoplastic drugs","volume":"94","author":"Krstev","year":"2003","journal-title":"Med Lav."},{"key":"B7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/1078155213497070","article-title":"Examining factors that influence the effectiveness of cleaning antineoplastic drugs from drug preparation surfaces: a pilot study","volume":"20","author":"Hon","year":"2014","journal-title":"J Oncol Pharm Pract"},{"key":"B8","unstructured":"Vyhlaska o spravne lekarenske praxi, blizs\u00ed2008"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12302-021-00544-5","article-title":"Levels and risks of antineoplastic drugs in households of oncology patients, hospices and retirement homes","volume":"33","author":"Bl\u00e1hov\u00e1","year":"2021","journal-title":"Environ Sci Eur."},{"key":"B10","doi-asserted-by":"publisher","first-page":"26810","DOI":"10.1007\/s11356-021-17607-y","article-title":"Levels and risks of surface contamination by thirteen antineoplastic drugs in the Czech and Slovak hospitals and pharmacies","volume":"29","author":"Dole\u017ealov\u00e1","year":"2022","journal-title":"Environ Sci Pollut Res."},{"key":"B11","volume-title":"Managing Hazardous Drug Exposures: Information for Healthcare Settings","year":"2023"},{"key":"B12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1177\/1078155217726160","article-title":"Survey of guidelines and current practices for safe handling of antineoplastic and other hazardous drugs used in 24 countries","volume":"25","author":"Mathias","year":"2019","journal-title":"J Oncol Pharm Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00420-006-0148-x","article-title":"Inhalation and dermal exposure to eight antineoplastic drugs in an industrial laundry facility","volume":"80","author":"Fransman","year":"2007","journal-title":"Int Arch Occup Environ Health."},{"key":"B14","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/ijpp.12590","article-title":"Biomonitoring of pharmacists and nurses at occupational risk from handling antineoplastic agents","volume":"28","author":"Santos","year":"2020","journal-title":"Int J Pharm Pract"},{"key":"B15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1570-0232(03)00100-4","article-title":"Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods","volume":"789","author":"Turci","year":"2003","journal-title":"J Chromatogr B."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchromb.2022.123411","article-title":"Urine biomonitoring of occupational exposure to methotrexate using a highly sensitive uhplc-ms\/ms method in mrm3 mode","volume":"1209","author":"Villa","year":"2022","journal-title":"SSRN Electron J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00420-021-01706-x","article-title":"Nurses' internal contamination by antineoplastic drugs in hospital centers: a cross-sectional descriptive study","volume":"94","author":"Villa","year":"2021","journal-title":"Int Arch Occup Environ Health."},{"key":"B18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/1078155212459667","article-title":"Exposure of family members to antineoplastic drugs via excreta of treated cancer patients","volume":"19","author":"Yuki","year":"2013","journal-title":"J Oncol Pharm Pract."},{"key":"B19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/1078155221992103","article-title":"Surface contamination with nine antineoplastic drugs in 109 canadian centers; 10 years of a monitoring program","volume":"28","author":"Chabut","year":"2021","journal-title":"J. Oncol. Pharm. Pract"},{"key":"B20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1080\/15459624.2016.1165912","article-title":"Surface wipe sampling for antineoplastic (chemotherapy) and other hazardous drug residue in healthcare settings: Methodology and recommendations","volume":"13","author":"Connor","year":"2016","journal-title":"J Occup Environ Hyg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/19338244.2013.763757","article-title":"Association of surface contamination by antineoplastic drugs with different working conditions in hospital pharmacies association of surface contamination by antineoplastic drugs with different working conditions in hospital pharmacies","volume":"693","author":"Odraska","year":"2014","journal-title":"Arch Environ Occup Health."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1177\/1078155220907125","article-title":"Cross-sectional evaluation of surface contamination with 9 antineoplastic drugs in 93 Canadian healthcare centers: 2019 results","volume":"26","author":"Palamini","year":"2020","journal-title":"J. Oncol. Pharm. Pract"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8601","DOI":"10.3390\/ijerph19148601","article-title":"Occupational exposure assessment to antineoplastic drugs in nine italian hospital centers over a 5-year survey program","volume":"19","author":"Sottani","year":"2022","journal-title":"Int J Environ Res Public Health."},{"key":"B24","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1007\/s00216-015-8868-y","article-title":"A surface wipe sampling and LC-MS\/MS method for the simultaneous detection of six antineoplastic drugs commonly handled by healthcare workers","volume":"407","author":"Jeronimo","year":"2015","journal-title":"Anal Bioanal Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00420-012-0742-z","article-title":"Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings","volume":"86","author":"Kopp","year":"2013","journal-title":"Int Arch Occup Environ Health."},{"key":"B26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/15459624.2020.1777296","article-title":"The application of novel field measurement and field evaluation protocols for assessing health care workers' exposure risk to antineoplastic drugs","volume":"17","author":"Astrakianakis","year":"2020","journal-title":"J Occup Environ Hyg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/annhyg\/mep050","article-title":"Guidance values for surface monitoring of antineoplastic drugs in german pharmacies","volume":"53","author":"Schierl","year":"2009","journal-title":"Ann Occup Hyg."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-21048-9_3","article-title":"Hospitals and Pharmacies as Sources of Contamination by Cytostatic Pharmaceuticals: Long-Term Monitoring in the Czech Republic,","author":"Blahova","year":"2020","journal-title":"Fate and Effects of Anticancer Drugs in the Environment. Springer Nature Switzerland AG, pp"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1177\/1078155218773862","article-title":"Surface contamination with ten antineoplastic drugs in 83 Canadian centers","volume":"25","author":"Chauchat","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/ejhpharm-2014-000549","article-title":"Evaluation of chemical contamination of surfaces during the preparation of chemotherapies in 24 hospital pharmacies","volume":"22","author":"Fleury-Souverain","year":"2015","journal-title":"Eur J Hosp Pharm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/annhyg\/mes081","article-title":"Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies-the MEWIP project","volume":"57","author":"Kiffmeyer","year":"2013","journal-title":"Ann Occup Hyg."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1097\/OP9.0000000000000024","article-title":"Environmental contamination with cytotoxic drugs in 15 hospitals from 11 European countries\u2014results of the MASHA project","volume":"3","author":"Korczowska","year":"2020","journal-title":"Eur J Oncol Pharm."},{"key":"B33","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/15459624.2017.1316389","article-title":"Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 66 canadian hospitals: a 2016 follow-up study","volume":"14","author":"Roland","year":"2017","journal-title":"J Occup Environ Hyg."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/annweh\/wxx065","article-title":"Monitoring surface contamination by antineoplastic drugs in Italian hospitals: Performance-based hygienic guidance values (HGVs) Project","volume":"61","author":"Sottani","year":"2017","journal-title":"Ann Work Expo Heal."},{"key":"B35","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0003-4878(00)00050-8","article-title":"Erratum: Postulating a dermal pathway for exposure to anti-neoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys","author":"Kromhout","year":"2000","journal-title":"Ann Occup Hyg 44."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.2146\/ajhp180564","article-title":"ASHP guidelines on handling hazardous drugs","volume":"75","author":"Power","year":"2018","journal-title":"Am J Heal Pharm."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1039\/c2em10704j","article-title":"Hygienic guidance values for wipe sampling of antineoplastic drugs in Swedish hospitals","volume":"14","author":"Hedmer","year":"2012","journal-title":"J Environ Monit."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00420-021-01731-w","article-title":"Occupational exposure to antineoplastic drugs: what about hospital sanitation personnel?","volume":"94","author":"Labr\u00e8che","year":"2021","journal-title":"Int Arch Occup Environ Health."},{"key":"B39","first-page":"3","article-title":"Environmental contamination with cytostatic drugs: past, present and future","volume":"12","author":"Sessink","year":"2011","journal-title":"Saf Considerations Oncol Pharm Special Ed."},{"key":"B40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/1078155217704990","article-title":"Carry-over of antineoplastic drug contamination in Dutch hospital pharmacies","volume":"24","author":"Crul","year":"2018","journal-title":"J Oncol Pharm Pract."},{"key":"B41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00420-021-01671-5","article-title":"The efficiency of antineoplastic drug contamination removal by widely used disinfectants\u2013laboratory and hospital studies","volume":"24","author":"Bl\u00e1hov\u00e1","year":"2021","journal-title":"Int Arch Occup Environ Health."},{"key":"B42","unstructured":"Study Supporting the Assessment of Different Options Concerning the Protection of Workers from Exposure to Hazardous Medicinal Products, including Cytotoxic Medicinal Products - Final Report, Publications Office\n            JespersenM\n            LassenC\n            MadsenP\n          2021"},{"key":"B43","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/annweh\/wxab013","article-title":"Spatial and temporal variability in antineoplastic drug surface contamination in cancer care centers in Alberta and Minnesota","volume":"65","author":"Jeronimo","year":"2021","journal-title":"Ann Work Expo Heal."},{"key":"B44","doi-asserted-by":"publisher","first-page":"wxac035","DOI":"10.1093\/annweh\/wxac035","article-title":"Application of an environmental monitoring to assess the practices and control the risk of occupational exposure to cyclophosphamide in two sites of a french comprehensive cancer center","volume":"2","author":"Acramel","year":"2021","journal-title":"Annal Work Exp Health."},{"key":"B45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.13075\/mp.5893.01288","article-title":"Monitoring of surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs)","volume":"73","author":"Dugheri","year":"2022","journal-title":"Med. Pr."},{"key":"B46","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4212\/cjhp.v70i6.1708","article-title":"Comparison of decontamination efficacy of cleaning solutions on a biological safety cabinet workbench contaminated by cyclophos- phamide","volume":"70","author":"Ad\u00e9","year":"2017","journal-title":"Can J Hosp Pharm."},{"key":"B47","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1177\/1078155219831427","article-title":"Efficiency of degradation or desorption methods in antineoplastic drug decontamination: a critical review","volume":"25","author":"Simon","year":"2019","journal-title":"J Oncol Pharm Pract."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00448","article-title":"Evolving best practice for take-home cancer drugs","author":"Pardhan","year":"2021","journal-title":"JCO Oncol Prac."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1235496\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T14:56:26Z","timestamp":1694703386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1235496\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":48,"alternative-id":["10.3389\/fpubh.2023.1235496"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1235496","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"article-number":"1235496"}}